Overpatented, Overpriced

Data on America's
Top 12 Drugs

Here's a summary dataset of the information we collected to create our Overpatented, Overpriced report series,
collating patent and market data.

Drug Total patent applications % filed after FDA approval Attempted years blocking generic competition Patents filed in U.S. vs. Europe Patents filed in U.S. vs. Japan % price increase
2012-2018
>5% Medicare
annual price increase
>10% Medicaid
annual price increase
Top 15 Medicare total spending (rank) Medicare spending per beneficiary Top 15 Medicaid total spending (rank) Years on U.S. market Generic / biosimilar approved Generic / biosimilar on the market
Herceptin 186 84% 48 2.4x 1.5x -58% - - - $34,000 - 20 -
Revlimid 106 40 2.7x 2.9x 79% - - ✔ 2 $75,238 - 13 - -
Humira 247 89% 39 3.3x 3.9x 144% ✔ 14 $34,024 ✔ 4 16 - -
Enbrel 57 72% 39 2.9x 3.2x 155% ✔ 15 $32,891 ✔ 13 20 -
Rituxan 204 90% 47 1.8x 1.8x 25% - ✔ 13 $23,815 - 21
Remicade 123 93% 32 6.1x 4.4x 18% - - $22,925 - 20
Eylea 67 37% 31 3.1x 4.4x 6% n/a n/a ✔ 7 $10,497 - 7 - -
Avastin 219 73% 43 2.2x 1.9x 16% - - - $5,360 - 14
Lyrica 118 21% 32 1.9x 1.9x 163% ✔ 8 $2,462 ✔ 9 14 - -
Xarelto 49 39% 34 tbd tbd 87% - ✔ 9 $2,420 - 7 - -
Lantus 74 95% 37 1.7x 3.1x 114% ✔ 3 $2,349 ✔ 2 18 -
Eliquis 48 35% 34 2.7x 2.8x 69% - - ✔ 10 $2,329 - 6 - -
Average 125 66% 38 2.8x 2.9x 68% $20,693 15
- Numbers in pink font indicate above the average for the 12 drugs.
- Data on prices and spending for Medicare and Medicaid were obtained from the CMS 'Drug Spending Database’ and reflect data from 2012-2016 (the most recent year available).
- Data on pricing changes from 2012-18 were obtained from IMS/IQVIA monthly price data and reflect total spending on prescription medicines from wholesaler transactions and include all on-invoice discounts, but no off-invoice discounts.

Join us to stay updated
and help make lifesaving medicines accessible to all